RCUS
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a significant premium to book value with no P/E available due to losses.
- High P/S ratio of 13.06
- P/B of 5.10
- No positive earnings for Graham valuation
Growth is evident in top-line revenue, but path to profitability remains unclear.
- 26.9% YoY revenue growth
- Strong analyst target of $34.00
- Continued high cash burn
Recent momentum is exceptionally strong despite long-term volatility.
- 1Y return of +197.9%
- Frequent earnings surprises
- 5Y change is still negative (-24.7%)
Strong balance sheet liquidity masks poor operational efficiency.
- Current Ratio 4.36
- Low Debt/Equity
- Piotroski F-Score 3/9
- Negative ROE/ROA
Typical for early-stage biotech focusing on R&D.
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for RCUS and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
RCUS
Arcus Biosciences, Inc.
Primary
|
-24.7% | +44.0% | +197.9% | +30.2% | +17.6% | +0.7% |
|
BEAM
Beam Therapeutics Inc.
Peer
|
-69.2% | -29.2% | +20.1% | +45.3% | +12.2% | +1.1% |
|
ICUI
ICU Medical, Inc.
Peer
|
-38.8% | -28.3% | -9.2% | +10.1% | -6.0% | +1.9% |
|
KNSA
Kiniksa Pharmaceuticals International, plc
Peer
|
+154.6% | +305.7% | +103.1% | +7.4% | -4.7% | +2.7% |
|
LEGN
Legend Biotech Corporation
Peer
|
-34.7% | -64.1% | -41.9% | -42.7% | -10.4% | -5.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
RCUS
Arcus Biosciences, Inc.
|
NEUTRAL | $3.23B | - | -63.3% | -142.9% | $25.68 | |
|
BEAM
Beam Therapeutics Inc.
|
BEARISH | $3.2B | - | -47.2% | -% | $31.56 | Compare |
|
ICUI
ICU Medical, Inc.
|
BEARISH | $3.14B | 4189.33 | 0.0% | 0.0% | $125.68 | Compare |
|
KNSA
Kiniksa Pharmaceuticals...
|
NEUTRAL | $3.34B | 58.15 | 11.7% | 8.7% | $43.61 | Compare |
|
LEGN
Legend Biotech Corporation
|
BEARISH | $3.36B | - | -29.1% | -28.8% | $18.16 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-23 | ROSEN TERRY JAY | Chief Executive Officer | Stock Award | 79,000 | - |
| 2026-01-23 | JAEN JUAN CARLOS | President | Stock Award | 31,000 | - |
| 2026-01-23 | GOELTZ ROBERT C. II | Chief Financial Officer | Stock Award | 24,000 | - |
| 2026-01-23 | JARRETT A JENNIFER | Chief Operating Officer | Stock Award | 31,000 | - |
| 2026-01-23 | AZOY ALEXANDER | Officer | Stock Award | 21,050 | - |
| 2026-01-23 | TANG CAROLYN C. | General Counsel | Stock Award | 24,000 | - |
| 2026-01-23 | MARKUS RICHARD M.D., PH.D. | Officer | Stock Award | 24,000 | - |
| 2026-01-08 | ROSEN TERRY JAY | Chief Executive Officer | Gift | 35,000 | - |
| 2026-01-05 | JAEN JUAN CARLOS | President | Sale | 31,823 | $681,342 |
| 2025-12-31 | GOELTZ ROBERT C. II | Chief Financial Officer | Sale | 6,552 | $153,186 |
| 2025-12-30 | ROSEN TERRY JAY | Chief Executive Officer | Gift | 2,400 | - |
| 2025-12-18 | AZOY ALEXANDER | Officer | Sale | 8,832 | $195,434 |
| 2025-12-17 | ROSEN TERRY JAY | Chief Executive Officer | Sale | 54,691 | $1,203,959 |
| 2025-12-17 | JAEN JUAN CARLOS | President | Sale | 21,208 | $466,870 |
| 2025-12-17 | GOELTZ ROBERT C. II | Chief Financial Officer | Sale | 12,662 | $278,739 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
RCUS faces significant regulatory risks due to the uncertain and rapidly evolving landscape of U.S. healthcare laws and reform. The company is exposed to potential investigations and costly settlements regarding its interactions with healthcare providers, which could divert management's attention and increase operational expenses.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning RCUS from our newsroom.